Opicapone

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 170 publications

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.

Journal: Journal of Parkinson's disease

Published: April 17, 2026

Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.

Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.

Journal: Brain sciences

Published: March 21, 2026

Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease.

Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: March 11, 2026

Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.

Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.

Journal: Annals of medicine

Published: March 05, 2026

Recent Developments in the Drug Treatment of Parkinson's Disease.

Recent Developments in the Drug Treatment of Parkinson's Disease.

Journal: Drugs

Published: January 15, 2026

Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment

Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment

Journal: Zeitschrift fur Gerontologie und Geriatrie

Published: December 19, 2025

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors.

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: December 15, 2025

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study.

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 05, 2025

Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis.

Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis.

Journal: Frontiers in neurology

Published: November 24, 2025

Patient-reported outcomes and experiences with COMT inhibitors in the management of motor fluctuations in Parkinson's disease: a UK-based nested cross-sectional study.

Patient-reported outcomes and experiences with COMT inhibitors in the management of motor fluctuations in Parkinson's disease: a UK-based nested cross-sectional study.

Journal: Journal of neurology

Published: November 24, 2025

Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules.

Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules.

Journal: Clinical neuropharmacology

Published: November 06, 2025

Real-world data of opicapone in patients with Parkinson's disease experiencing motor fluctuations: the OPTIMO study.

Real-world data of opicapone in patients with Parkinson's disease experiencing motor fluctuations: the OPTIMO study.

Journal: Frontiers in neurology

Published: November 03, 2025

Showing 1-12 of 170

Last Updated: 06/30/2026